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StevenseJohnson syndrome (SJS) and toxic epidermal necrolysis
(TEN), which are severe cutaneous adverse reactions, are associated
with fatal disorders.1 Although many causes of SJS/TEN have been
proposed, their pathogenesis is not fully understood. Hypersensi-
tivity to medications accounts for the majority of cases of SJS/
TEN.2 Several research groups have presented reports on drugs
implicated in SJS/TEN (selective cyclooxygenase-2 inhibitors, lamo-
trigine, anti-epileptic drugs, sulfonamide antibiotics, and allopu-
rinol, etc.).3,4 SJS associated with Mycoplasma pneumoniae
infection is observed mainly in children,5,6 while another group re-
ported the effects of the genetic background of patients.7 The rela-
tionship between aging and SJS/TEN is still not clear.
Since SJS/TEN are very rare diseases,1 the implementation phase
of epidemiologic research is fraught with difﬁculties. The US Food
and Drug Administration (FDA) Adverse Event Reporting System
(FAERS) is the largest and most well-known database worldwide,
and it reﬂects the realities of clinical practice.8 FAERS, therefore,
is one of the primary tools used in pharmacovigilance.
We examined the incidence of SJS/TEN in the FAERS database
from January 2004 to March 2013. To extract case reports of SJS/
TEN from the FAERS database, SJS/TEN were coded according to
the terminology preferred by the Medical Dictionary for Regulatory
Activities 16.0. We used the following three preferred terms to
match SJS and TEN: SJS/PT10042033, oculomucocutaneous syn-
drome/PT10030081, and TEN/PT10044223. To detect SJS/TEN inci-
dences, we calculated the reporting odds ratio (ROR), which is
established for pharmacovigilance by using a disproportionality
analysis.8 The ROR is an applicable technique that allows for adjust-
ment through logistic regression analysis and offers the advanta-
geous possibility of controlling for covariates.9 We reﬁned the
results with a dedicated correction to detect possible confounders
present in the database. The reports were stratiﬁed by age as fol-
lows: 17 years, 18e39 years, 40e59 years, 60e79 years, and
80 years. The RORs were adjusted for gender, reporting year,
and stratiﬁed age group. The following logistic model was used:
Log (odds) ¼ b0 þ b1Y þ b2G þ b3A
where Y ¼ reporting year, G ¼ gender, and A ¼ stratiﬁed age group.
The FAERS contains 4,746,890 reports. After excluding dupli-
cates according to the FDA recommendation and extracting the re-
ports completed with gender and age information, 2,257,902Peer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).reports were ﬁnally analyzed. The number of reports obtained for
each preferred term was 9078 for SJS, 192 for oculomucocutaneous
syndrome, and 4076 for TEN. Table 1 summarizes the scores and the
reporting ratios. The breakdown of the number of case reports on
valdecoxib, lamotrigine, phenytoin, acetaminophen, and furose-
mide was 1446 (11.0%), 1341 (3.6%), 1076 (6.1%), 834 (0.6%), and
739 (0.8%), respectively. The age-groups of patients with SJS/TEN
ranged from infants to the elderly. The number of reported cases
was high in the 40- to 79-year-old group. The RORs for the 17-
year-old group indicated the highest values for both genders. We
further examined the data with the adjusted RORs (Table 2). The ef-
fect of the term 17 years was statistically signiﬁcant in the likeli-
hood ratio test (P < 0.0001). The adjusted ROR of the 17-year-old
patients in the whole data extracted from the FAERS database was
2.87 (2.67e3.07) at a 95% conﬁdence interval (CI). The adjusted
RORs (95% CI) of valdecoxib, lamotrigine, phenytoin, acetamino-
phen, and furosemide were 2.54 (0.40e8.98), 2.90 (2.44e3.45),
2.28 (1.79e2.88), 6.15 (4.95e7.62), and 1.58 (0.96e2.46),
respectively.
To the best of our knowledge, systematic studies of SJS/TEN that
are stratiﬁed by age group are very rare. In this study, we demon-
strated a relatively high value for the adjusted ROR in patients
aged 17 years. We do not have a conclusive explanation for these
data. Reports of SJS due to viral infections in young patients who
also received acetaminophen might be included in the data. There-
fore, acetaminophen may be a causal drug and may explain the
high incidence of SJS/TEN in young patients. The pharmacological
actions of valdecoxib, lamotrigine, phenytoin, and furosemide are
different from that of acetaminophen. Valdecoxib, lamotrigine,
phenytoin, and furosemide showed high values for the adjusted
RORs in the 17-year-old group. The numbers of reports on valde-
coxib, lamotrigine, and phenytoin were higher than the number of
reports on acetaminophen. We considered that mycoplasma infec-
tion could partially explain the high value of the adjusted RORs of
SJS/TEN in the 17-year-old patients.
Another plausible reason for this might be differences in sensi-
tivity to medication between patients aged 17 years and elderly
patients. SJS/TEN are also believed to be partially immune-
mediated, since treating patients with the same drug repeatedly
can be associated with the rapid recurrence of SJS/TEN.10
On the other hand, the genetic background related to the human
leukocyte antigen might have an inﬂuence on the incidence of SJS/
TEN.7 Genetic factors that are associated with drug hypersensitivity
are a complex issue. In evaluations of the true risk of medications,
regional differences in drug prescriptions should be taken into ac-
count. The impact of human leukocyte antigen genotyping shouldvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
SJS/TEN in the FDA-adverse event reporting system database (January 2004eMarch 2013).
Gender Total Vardecoxib Lamotrigine Phenytoin Acetaminophen Furosemide
Reported cases Reporting
ratio
(%)
Reported cases Reporting
ratio
(%)
Reported cases Reporting
ratio
(%)
Reported cases Reporting
ratio
(%)
Reported cases Reporting
ratio
(%)
Reported cases Reporting
ratio
(%)
SJS or TEN Total SJS or TEN Total SJS or TEN Total SJS or TEN Total SJS or TEN Total SJS or TEN Total
Total 12,279 3,522,995 0.3 1446 13,105 11.0 1341 36,817 3.6 1076 17,510 6.1 834 137,968 0.6 739 96,686 0.8
Stratiﬁed by agey
17 years M 620 65,307 0.9 1 4 25.0 111 1460 7.6 67 548 12.2 85 2347 3.6 16 761 2.1
F 563 56,120 1.0 1 16 6.3 149 1639 9.1 45 417 10.8 67 2576 2.6 4 643 0.6
18e39 years M 697 127,899 0.5 12 186 6.5 92 2693 3.4 49 1106 4.4 73 6410 1.1 23 1117 2.1
F 1231 286,740 0.4 25 329 7.6 310 6992 4.4 96 1321 7.3 80 14,295 0.6 25 1975 1.3
40e59 years M 1096 296,747 0.4 40 1087 3.7 89 3013 3.0 91 2214 4.1 90 14,281 0.6 90 7729 1.2
F 1443 491,273 0.3 64 1426 4.5 208 6621 3.1 155 2310 6.7 102 24,254 0.4 67 9664 0.7
60e79 years M 1139 328,040 0.3 41 938 4.4 32 1139 2.8 69 1687 4.1 80 14,109 0.6 150 19,915 0.8
F 1307 429,293 0.3 54 1544 3.5 58 1988 2.9 106 1809 5.9 110 19,877 0.6 194 20,774 0.9
80 years M 234 69,164 0.3 6 123 4.9 4 144 2.8 6 340 1.8 8 3348 0.2 31 7508 0.4
F 377 107,319 0.4 16 376 4.3 8 236 3.4 22 446 4.9 36 6238 0.6 71 10,879 0.7
Subtotal 8707 2,257,902 0.4 260 6029 4.3 1061 25,925 4.1 706 12,198 5.8 731 107,735 0.7 671 80,965 0.8
y Completed with age and gender.
Table 2
Adjusted reporting odds ratio of SJS/TEN stratiﬁed by age.
Total Valdecoxib Lamotrigine Phenytoin Acetaminophen Furosemide
Adjusted ROR (95%CI) Adjusted ROR (95%CI) Adjusted ROR (95%CI) Adjusted ROR (95%CI) Adjusted ROR (95%CI) Adjusted ROR (95%CI)
Reporting year 0.92 (0.91e0.92) 0.98 (0.91e1.05) 0.96 (0.94e0.98) 1.12 (1.09e1.16) 0.96 (0.93e0.98) 0.93 (0.90e0.95)
Gender female 0.87 (0.84e0.91) 0.99 (0.77e1.29) 1.16 (1.01e1.33) 1.46 (1.25e1.71) 0.74 (0.64e0.86) 1.00 (0.86e1.16)
Age
17 years 2.87 (2.67e3.07) 2.54 (0.40e8.98) 2.90 (2.44e3.45) 2.28 (1.79e2.88) 6.15 (4.95e7.62) 1.58 (0.96e2.46)
18e39 years 1.46 (1.37e1.55) 1.79 (1.20e2.62) 1.35 (1.16e1.57) 1.08 (0.87e1.34) 1.54 (1.24e1.90) 1.76 (1.26e2.41)
40e59 yearsy 1.00 1.00 1.00 1.00 1.00 1.00
60e79 years 0.99 (0.93e1.04) 0.91 (0.69e1.22) 0.95 (0.74e1.20) 0.92 (0.76e1.13) 1.10 (0.90e1.35) 0.94 (0.78e1.14)
80 years 1.06 (0.97e1.16) 1.05 (0.63e1.65) 1.03 (0.54e1.78) 0.65 (0.43e0.95) 0.92 (0.66e1.27) 0.62 (0.48e0.79)
y As reference.
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ing well-organized epidemiologic studies, the FAERS database, or
both.
The FAERS database is subject to many biases such as under-
reporting, over-reporting, and confounding by comorbidities.8 In
general, the crude ROR is inapplicable to inferences of comparative
strengths of causality and only offers a rough indication of the
signal strength.8 The FAERS database is a spontaneous reporting
database system and detailed patient information is not included.
Therefore, the deﬁnition of SJS/TEN in the FAERS database is not
stringent. We must highlight this profound limitation in the FAERS
database. Despite such limitations that are inherent to spontaneous
reporting, it may be acceptable to compare the adjusted RORs of a
particular event that are derived from stratiﬁed analysis within a
particular context.
This studywas the ﬁrst to evaluate the relationship between SJS/
TEN and aging by using the FAERS database. We hope that these
data will update the information available to clinicians and be
potentially useful for improving the management of SJS/TEN.Acknowledgments
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